Structured Review

Phoenix Pharmaceuticals damgo
<t>Endothelin</t> effects on channel mutants A , diagrams depict channel mutants: Kir3.4 (S143T) parent, N-terminal truncation, and chimeras. We produced the Kir3.4(S143T) using a cDNA template for cRNA coding a Kir3.4(S143T) having a truncated (1–57) N terminus. We used Kir3 chimeras: Kir3.4(S143T)-(1–338)/Kir3.1-(333–501) and Kir3.4(S143T)-(1–249)/Kir3.1-(244–501). B , oocytes were injected with 1 ng of MOR and 1 ng of HETAR, and either 1 ng of Kir3.4(S143T), 1 ng of Kir3.4(S143T)-(Δ1–57), 1 ng of Kir3.4(S143T)-(1–338)/Kir3.1-(333–501), or 1 ng of Kir3.4(S143T)-(1–249)/Kir3.1-(244–501). The percent inhibition of the second mu opioid response after Et-1 pretreatment is shown. The bar graph summarizes the effects of Et-1 on the <t>DAMGO</t> activation of MOR compared with untreated controls from the same batch. Data are means ± S.E. from four to seven oocytes and two to three independent experiments.
Damgo, supplied by Phoenix Pharmaceuticals, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/damgo/product/Phoenix Pharmaceuticals
Average 92 stars, based on 1 article reviews
Price from $9.99 to $1999.99
damgo - by Bioz Stars, 2020-09
92/100 stars

Images

1) Product Images from "Eicosanoids Inhibit the G-protein-gated Inwardly Rectifying Potassium Channel (Kir3) at the Na+/PIP2 Gating Site *"

Article Title: Eicosanoids Inhibit the G-protein-gated Inwardly Rectifying Potassium Channel (Kir3) at the Na+/PIP2 Gating Site *

Journal: The Journal of biological chemistry

doi: 10.1074/jbc.M010097200

Endothelin effects on channel mutants A , diagrams depict channel mutants: Kir3.4 (S143T) parent, N-terminal truncation, and chimeras. We produced the Kir3.4(S143T) using a cDNA template for cRNA coding a Kir3.4(S143T) having a truncated (1–57) N terminus. We used Kir3 chimeras: Kir3.4(S143T)-(1–338)/Kir3.1-(333–501) and Kir3.4(S143T)-(1–249)/Kir3.1-(244–501). B , oocytes were injected with 1 ng of MOR and 1 ng of HETAR, and either 1 ng of Kir3.4(S143T), 1 ng of Kir3.4(S143T)-(Δ1–57), 1 ng of Kir3.4(S143T)-(1–338)/Kir3.1-(333–501), or 1 ng of Kir3.4(S143T)-(1–249)/Kir3.1-(244–501). The percent inhibition of the second mu opioid response after Et-1 pretreatment is shown. The bar graph summarizes the effects of Et-1 on the DAMGO activation of MOR compared with untreated controls from the same batch. Data are means ± S.E. from four to seven oocytes and two to three independent experiments.
Figure Legend Snippet: Endothelin effects on channel mutants A , diagrams depict channel mutants: Kir3.4 (S143T) parent, N-terminal truncation, and chimeras. We produced the Kir3.4(S143T) using a cDNA template for cRNA coding a Kir3.4(S143T) having a truncated (1–57) N terminus. We used Kir3 chimeras: Kir3.4(S143T)-(1–338)/Kir3.1-(333–501) and Kir3.4(S143T)-(1–249)/Kir3.1-(244–501). B , oocytes were injected with 1 ng of MOR and 1 ng of HETAR, and either 1 ng of Kir3.4(S143T), 1 ng of Kir3.4(S143T)-(Δ1–57), 1 ng of Kir3.4(S143T)-(1–338)/Kir3.1-(333–501), or 1 ng of Kir3.4(S143T)-(1–249)/Kir3.1-(244–501). The percent inhibition of the second mu opioid response after Et-1 pretreatment is shown. The bar graph summarizes the effects of Et-1 on the DAMGO activation of MOR compared with untreated controls from the same batch. Data are means ± S.E. from four to seven oocytes and two to three independent experiments.

Techniques Used: Produced, Injection, Inhibition, Activation Assay

2) Product Images from "?-Opioid receptor stimulation in the nucleus accumbens elevates fatty tastant intake by increasing palatability and suppressing satiety signals"

Article Title: ?-Opioid receptor stimulation in the nucleus accumbens elevates fatty tastant intake by increasing palatability and suppressing satiety signals

Journal: American Journal of Physiology - Regulatory, Integrative and Comparative Physiology

doi: 10.1152/ajpregu.00406.2010

A : mean ± SE olestra intake after DAMGO infusion into the NAcc core. B : mean olestra intake after DAMGO and/or CTAP infusion into the NAcc core. Different letters indicate statistically significant differences.
Figure Legend Snippet: A : mean ± SE olestra intake after DAMGO infusion into the NAcc core. B : mean olestra intake after DAMGO and/or CTAP infusion into the NAcc core. Different letters indicate statistically significant differences.

Techniques Used:

Infusion sites. A : circles indicate NAcc core ( left ) and shell ( right ) infusion sites for experiment 1b (lick microstructure). Black circles (NAcc core, left ) indicate core infusion sites also used in experiment 2 (olestra intake). B : triangles indicate NAcc core infusion sites for experiment 3 (NAcc, DAMGO, and icv MTII coinfusion). Numbers ( left ) indicate anterioposterior position of coronal slices.
Figure Legend Snippet: Infusion sites. A : circles indicate NAcc core ( left ) and shell ( right ) infusion sites for experiment 1b (lick microstructure). Black circles (NAcc core, left ) indicate core infusion sites also used in experiment 2 (olestra intake). B : triangles indicate NAcc core infusion sites for experiment 3 (NAcc, DAMGO, and icv MTII coinfusion). Numbers ( left ) indicate anterioposterior position of coronal slices.

Techniques Used:

DAMGO effects on 5% Intralipid consumption after infusion into the NAcc core ( A–C ) or shell ( D–F ). Mean ± SE first-minute licks ( A and D ), burst duration ( B and E ), and burst number ( C and F ) following NAcc DAMGO infusion. Different letters indicate statistically significant differences.
Figure Legend Snippet: DAMGO effects on 5% Intralipid consumption after infusion into the NAcc core ( A–C ) or shell ( D–F ). Mean ± SE first-minute licks ( A and D ), burst duration ( B and E ), and burst number ( C and F ) following NAcc DAMGO infusion. Different letters indicate statistically significant differences.

Techniques Used:

A : mean ± SE consumption of high-fat chow following drug infusion into the NAcc core (saline or 125 ng DAMGO/NAcc) and third ventricle (third V; saline or 0.8 μg MTII). B : time spent feeding during consecutive 10-min bins during 1-h test session. C : latency to begin feeding. Different letters indicate statistically significant differences.
Figure Legend Snippet: A : mean ± SE consumption of high-fat chow following drug infusion into the NAcc core (saline or 125 ng DAMGO/NAcc) and third ventricle (third V; saline or 0.8 μg MTII). B : time spent feeding during consecutive 10-min bins during 1-h test session. C : latency to begin feeding. Different letters indicate statistically significant differences.

Techniques Used:

3) Product Images from "A novel luminescence-based β-arrestin membrane recruitment assay for unmodified GPCRs"

Article Title: A novel luminescence-based β-arrestin membrane recruitment assay for unmodified GPCRs

Journal: bioRxiv

doi: 10.1101/2020.04.09.034520

MeNArC assay with dose-response curves for β-arrestin2 membrane recruitment with the µ-opioid receptor (MOR) and cannabinoid 1 receptor (CB1R). The agonist DAMGO and the antagonist naxolone were used for MOR and the agonist WN552122 and antagonist rimonabant were used for CB1R.
Figure Legend Snippet: MeNArC assay with dose-response curves for β-arrestin2 membrane recruitment with the µ-opioid receptor (MOR) and cannabinoid 1 receptor (CB1R). The agonist DAMGO and the antagonist naxolone were used for MOR and the agonist WN552122 and antagonist rimonabant were used for CB1R.

Techniques Used:

Related Articles

other:

Article Title: ?-Opioid receptor stimulation in the nucleus accumbens elevates fatty tastant intake by increasing palatability and suppressing satiety signals
Article Snippet: In this experiment, we tested the effects of coinfusion of DAMGO (control saline or 250 ng/μl, 0.5 μl/NAcc) into the NAcc core and the melanocortin agonist MTII (Phoenix Pharmaceuticals, Mountain View, CA; control saline or 0.8 μg in 1 μl) into the third ventricle on consumption of a high-fat chow (Bio-Serv, Frenchtown, NJ).

Article Title: A novel luminescence-based β-arrestin membrane recruitment assay for unmodified GPCRs
Article Snippet: Compounds Dopamine hydrochloride (#H-8502) and angiotensin II (#A9525) were purchased from Sigma-Aldrich (St. Louis, MO, USA); sulpiride (#0895), olmesartan (#4616), Dynorphin B (#3196), naloxone hydrochloride (#0599), WN552122 (#1038) and rimonabant hydrochloride (#0923) from Tocris (Bristol, UK); DAMGO (#024-10) from Phoenix Pharmaceuticals and rapamycin (#tlrl-rap) from Invivogen (San Diego, CA, USA).

Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92
    Phoenix Pharmaceuticals damgo
    <t>Endothelin</t> effects on channel mutants A , diagrams depict channel mutants: Kir3.4 (S143T) parent, N-terminal truncation, and chimeras. We produced the Kir3.4(S143T) using a cDNA template for cRNA coding a Kir3.4(S143T) having a truncated (1–57) N terminus. We used Kir3 chimeras: Kir3.4(S143T)-(1–338)/Kir3.1-(333–501) and Kir3.4(S143T)-(1–249)/Kir3.1-(244–501). B , oocytes were injected with 1 ng of MOR and 1 ng of HETAR, and either 1 ng of Kir3.4(S143T), 1 ng of Kir3.4(S143T)-(Δ1–57), 1 ng of Kir3.4(S143T)-(1–338)/Kir3.1-(333–501), or 1 ng of Kir3.4(S143T)-(1–249)/Kir3.1-(244–501). The percent inhibition of the second mu opioid response after Et-1 pretreatment is shown. The bar graph summarizes the effects of Et-1 on the <t>DAMGO</t> activation of MOR compared with untreated controls from the same batch. Data are means ± S.E. from four to seven oocytes and two to three independent experiments.
    Damgo, supplied by Phoenix Pharmaceuticals, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/damgo/product/Phoenix Pharmaceuticals
    Average 92 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    damgo - by Bioz Stars, 2020-09
    92/100 stars
      Buy from Supplier

    Image Search Results


    Endothelin effects on channel mutants A , diagrams depict channel mutants: Kir3.4 (S143T) parent, N-terminal truncation, and chimeras. We produced the Kir3.4(S143T) using a cDNA template for cRNA coding a Kir3.4(S143T) having a truncated (1–57) N terminus. We used Kir3 chimeras: Kir3.4(S143T)-(1–338)/Kir3.1-(333–501) and Kir3.4(S143T)-(1–249)/Kir3.1-(244–501). B , oocytes were injected with 1 ng of MOR and 1 ng of HETAR, and either 1 ng of Kir3.4(S143T), 1 ng of Kir3.4(S143T)-(Δ1–57), 1 ng of Kir3.4(S143T)-(1–338)/Kir3.1-(333–501), or 1 ng of Kir3.4(S143T)-(1–249)/Kir3.1-(244–501). The percent inhibition of the second mu opioid response after Et-1 pretreatment is shown. The bar graph summarizes the effects of Et-1 on the DAMGO activation of MOR compared with untreated controls from the same batch. Data are means ± S.E. from four to seven oocytes and two to three independent experiments.

    Journal: The Journal of biological chemistry

    Article Title: Eicosanoids Inhibit the G-protein-gated Inwardly Rectifying Potassium Channel (Kir3) at the Na+/PIP2 Gating Site *

    doi: 10.1074/jbc.M010097200

    Figure Lengend Snippet: Endothelin effects on channel mutants A , diagrams depict channel mutants: Kir3.4 (S143T) parent, N-terminal truncation, and chimeras. We produced the Kir3.4(S143T) using a cDNA template for cRNA coding a Kir3.4(S143T) having a truncated (1–57) N terminus. We used Kir3 chimeras: Kir3.4(S143T)-(1–338)/Kir3.1-(333–501) and Kir3.4(S143T)-(1–249)/Kir3.1-(244–501). B , oocytes were injected with 1 ng of MOR and 1 ng of HETAR, and either 1 ng of Kir3.4(S143T), 1 ng of Kir3.4(S143T)-(Δ1–57), 1 ng of Kir3.4(S143T)-(1–338)/Kir3.1-(333–501), or 1 ng of Kir3.4(S143T)-(1–249)/Kir3.1-(244–501). The percent inhibition of the second mu opioid response after Et-1 pretreatment is shown. The bar graph summarizes the effects of Et-1 on the DAMGO activation of MOR compared with untreated controls from the same batch. Data are means ± S.E. from four to seven oocytes and two to three independent experiments.

    Article Snippet: Endothelin-1 and DAMGO were obtained from Phoenix Pharmaceuticals, Belmont, CA and were stored at −20 °C until use.

    Techniques: Produced, Injection, Inhibition, Activation Assay

    A : mean ± SE olestra intake after DAMGO infusion into the NAcc core. B : mean olestra intake after DAMGO and/or CTAP infusion into the NAcc core. Different letters indicate statistically significant differences.

    Journal: American Journal of Physiology - Regulatory, Integrative and Comparative Physiology

    Article Title: ?-Opioid receptor stimulation in the nucleus accumbens elevates fatty tastant intake by increasing palatability and suppressing satiety signals

    doi: 10.1152/ajpregu.00406.2010

    Figure Lengend Snippet: A : mean ± SE olestra intake after DAMGO infusion into the NAcc core. B : mean olestra intake after DAMGO and/or CTAP infusion into the NAcc core. Different letters indicate statistically significant differences.

    Article Snippet: In this experiment, we tested the effects of coinfusion of DAMGO (control saline or 250 ng/μl, 0.5 μl/NAcc) into the NAcc core and the melanocortin agonist MTII (Phoenix Pharmaceuticals, Mountain View, CA; control saline or 0.8 μg in 1 μl) into the third ventricle on consumption of a high-fat chow (Bio-Serv, Frenchtown, NJ).

    Techniques:

    Infusion sites. A : circles indicate NAcc core ( left ) and shell ( right ) infusion sites for experiment 1b (lick microstructure). Black circles (NAcc core, left ) indicate core infusion sites also used in experiment 2 (olestra intake). B : triangles indicate NAcc core infusion sites for experiment 3 (NAcc, DAMGO, and icv MTII coinfusion). Numbers ( left ) indicate anterioposterior position of coronal slices.

    Journal: American Journal of Physiology - Regulatory, Integrative and Comparative Physiology

    Article Title: ?-Opioid receptor stimulation in the nucleus accumbens elevates fatty tastant intake by increasing palatability and suppressing satiety signals

    doi: 10.1152/ajpregu.00406.2010

    Figure Lengend Snippet: Infusion sites. A : circles indicate NAcc core ( left ) and shell ( right ) infusion sites for experiment 1b (lick microstructure). Black circles (NAcc core, left ) indicate core infusion sites also used in experiment 2 (olestra intake). B : triangles indicate NAcc core infusion sites for experiment 3 (NAcc, DAMGO, and icv MTII coinfusion). Numbers ( left ) indicate anterioposterior position of coronal slices.

    Article Snippet: In this experiment, we tested the effects of coinfusion of DAMGO (control saline or 250 ng/μl, 0.5 μl/NAcc) into the NAcc core and the melanocortin agonist MTII (Phoenix Pharmaceuticals, Mountain View, CA; control saline or 0.8 μg in 1 μl) into the third ventricle on consumption of a high-fat chow (Bio-Serv, Frenchtown, NJ).

    Techniques:

    DAMGO effects on 5% Intralipid consumption after infusion into the NAcc core ( A–C ) or shell ( D–F ). Mean ± SE first-minute licks ( A and D ), burst duration ( B and E ), and burst number ( C and F ) following NAcc DAMGO infusion. Different letters indicate statistically significant differences.

    Journal: American Journal of Physiology - Regulatory, Integrative and Comparative Physiology

    Article Title: ?-Opioid receptor stimulation in the nucleus accumbens elevates fatty tastant intake by increasing palatability and suppressing satiety signals

    doi: 10.1152/ajpregu.00406.2010

    Figure Lengend Snippet: DAMGO effects on 5% Intralipid consumption after infusion into the NAcc core ( A–C ) or shell ( D–F ). Mean ± SE first-minute licks ( A and D ), burst duration ( B and E ), and burst number ( C and F ) following NAcc DAMGO infusion. Different letters indicate statistically significant differences.

    Article Snippet: In this experiment, we tested the effects of coinfusion of DAMGO (control saline or 250 ng/μl, 0.5 μl/NAcc) into the NAcc core and the melanocortin agonist MTII (Phoenix Pharmaceuticals, Mountain View, CA; control saline or 0.8 μg in 1 μl) into the third ventricle on consumption of a high-fat chow (Bio-Serv, Frenchtown, NJ).

    Techniques:

    A : mean ± SE consumption of high-fat chow following drug infusion into the NAcc core (saline or 125 ng DAMGO/NAcc) and third ventricle (third V; saline or 0.8 μg MTII). B : time spent feeding during consecutive 10-min bins during 1-h test session. C : latency to begin feeding. Different letters indicate statistically significant differences.

    Journal: American Journal of Physiology - Regulatory, Integrative and Comparative Physiology

    Article Title: ?-Opioid receptor stimulation in the nucleus accumbens elevates fatty tastant intake by increasing palatability and suppressing satiety signals

    doi: 10.1152/ajpregu.00406.2010

    Figure Lengend Snippet: A : mean ± SE consumption of high-fat chow following drug infusion into the NAcc core (saline or 125 ng DAMGO/NAcc) and third ventricle (third V; saline or 0.8 μg MTII). B : time spent feeding during consecutive 10-min bins during 1-h test session. C : latency to begin feeding. Different letters indicate statistically significant differences.

    Article Snippet: In this experiment, we tested the effects of coinfusion of DAMGO (control saline or 250 ng/μl, 0.5 μl/NAcc) into the NAcc core and the melanocortin agonist MTII (Phoenix Pharmaceuticals, Mountain View, CA; control saline or 0.8 μg in 1 μl) into the third ventricle on consumption of a high-fat chow (Bio-Serv, Frenchtown, NJ).

    Techniques:

    MeNArC assay with dose-response curves for β-arrestin2 membrane recruitment with the µ-opioid receptor (MOR) and cannabinoid 1 receptor (CB1R). The agonist DAMGO and the antagonist naxolone were used for MOR and the agonist WN552122 and antagonist rimonabant were used for CB1R.

    Journal: bioRxiv

    Article Title: A novel luminescence-based β-arrestin membrane recruitment assay for unmodified GPCRs

    doi: 10.1101/2020.04.09.034520

    Figure Lengend Snippet: MeNArC assay with dose-response curves for β-arrestin2 membrane recruitment with the µ-opioid receptor (MOR) and cannabinoid 1 receptor (CB1R). The agonist DAMGO and the antagonist naxolone were used for MOR and the agonist WN552122 and antagonist rimonabant were used for CB1R.

    Article Snippet: Compounds Dopamine hydrochloride (#H-8502) and angiotensin II (#A9525) were purchased from Sigma-Aldrich (St. Louis, MO, USA); sulpiride (#0895), olmesartan (#4616), Dynorphin B (#3196), naloxone hydrochloride (#0599), WN552122 (#1038) and rimonabant hydrochloride (#0923) from Tocris (Bristol, UK); DAMGO (#024-10) from Phoenix Pharmaceuticals and rapamycin (#tlrl-rap) from Invivogen (San Diego, CA, USA).

    Techniques: